It has also been identified as a tumor suppressor in breast cancer metastasis, where its effects may be mediated by redox signaling, positioning TAGLN2 as a critical regulator of the ROS/NF-κB pathway in breast cancer [87]. The gene discussed is NFKB1; the disease is breast carcinoma.